本帖最后由 老马 于 2012-1-13 21:20 编辑
/ r& H. F6 X3 j X
* ?$ ~2 b5 b9 s" v# x( H爱必妥和阿瓦斯丁的比较
# q" o0 w0 W8 [' a8 M; W
" G, m6 @0 M4 d( @2 R/ D
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
* _ H( e/ g+ A9 y
+ j, n/ V3 ?' k& l
) J3 p$ i1 F/ y& D3 f) A* ^1 E
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
) s0 _" P% F( g |. V==================================================
: T$ [6 @ g4 u& v* |% U# ^/ B2 EOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ I e& Y+ Q$ U3 [1 ePatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 T: k; K. P' J2 E% a2 _" H
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.$ T9 K' R" S6 K' ^
|